

FEB 27 2004

## FACSIMILE COVER SHEET

**Licata & Tyrrell P.C.**66 E. Main Street  
Marlton, New Jersey

Tel: (856) 810-1515

Fax: (856) 810-1454

E-Mail: JMLicata@licataandtyrrell.com

February 27, 2004

**OFFICIAL****GROUP: 1635****FAX NUMBER: 1-703-872-9306****ATTORNEY DOCKET NO.: ISPH-0625****SERIAL NO.: 10/057,550****FILED: January 25, 2002****NUMBER OF PAGES: 11**  
(including this sheet)

**MESSAGE:** Attached is a General Transmittal Letter (in duplicate);  
four Terminal Disclaimers and  
Authorization to charge deposit account \$440.00 for Terminal Disclaimer fees  
(\$110.00 for each Terminal Disclaimer).

**URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!**

\* \* \* \* \*

If you have any questions, or did not receive the proper number of pages, or had trouble  
during transmission, please call 856-810-1515.

**CONFIDENTIALITY NOTICE**

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying, distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney-client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

<b>TRANSMITTAL LETTER</b> (General - Patent Pending)			Docket No. <b>ISPH-0625</b>
In Re Application Of: <b>Brett P. Monia</b>			
Serial No. <b>10/057,550</b>	Filing Date <b>January 25, 2002</b>	Examiner <b>James Schultz</b>	Group Art Unit <b>1635</b>
Title: <b>ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION</b>			
<p style="text-align: center;"><u>TO THE COMMISSIONER FOR PATENTS:</u></p> <p>Transmitted herewith is:</p> <p style="margin-left: 40px;"><b>Four Terminal Disclaimers</b></p> <p>In the above identified application.</p> <p><input type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <b>50-1619</b> as described below.</p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> Charge the amount of <b>\$440.00</b></p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> Credit any overpayment.</p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> Charge any additional fee required.</p> <div style="display: flex; justify-content: space-between;"><div style="width: 45%;"><p>_____ <i>Jane Massey Licata</i> Signature</p><p><b>Jane Massey Licata</b> Reg. No. 32,257 Licata &amp; Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454</p></div><div style="width: 45%; text-align: right;"><p>Dated: <b>February 27, 2004</b></p></div></div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p><p style="text-align: center;">_____ Signature of Person Mailing Correspondence</p><p style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</p></div> <p>CC:</p>			

RECEIVED

CENTRAL FAX CENTER

TRANSMITTAL LETTER  
(General - Patent Pending)

FEB 27 2004

Docket No.  
ISP#-0625

In Re Application Of: Brett P. Monia

OFFICIAL

Serial No.  
10/057,550Filing Date  
January 25, 2002Examiner  
James SchultzGroup Art Unit  
1635

Title: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION


TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Four Terminal Disclaimers

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-1619 as described below.
- ☒ Charge the amount of \$440.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.



Signature

Dated: February 27, 2004

Jane Massey Licata  
Reg. No. 32,257  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053  
Tel: 856-810-1515  
Fax: 856-810-1454


I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

cc:



<b>Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent</b>			Docket No. <b>ISPH-0625</b>
In Re Application Of: <b>Brett P. Monia</b>			
Serial No. <b>10/057,550</b>	Filing Date <b>January 25, 2002</b>	Examiner <b>James Schultz</b>	Group Art Unit <b>1635</b>
Invention: <b>ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION</b>			
Owner of Record: <b>Isis Pharmaceuticals, Inc.</b>			
<u><b>TO THE COMMISSIONER FOR PATENTS:</b></u>			
<p>The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,410,518. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.</p> <p>In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.</p> <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney of record.</p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"><div style="width: 45%;"><p style="text-align: center;"> _____ Signature</p><p style="text-align: center;"><b>Jane Massey Licata</b> _____ Typed or Printed Name</p></div><div style="width: 45%; text-align: right;"><p>Dated: February 27, 2004</p></div></div> <div style="margin-top: 10px;"><p><input checked="" type="checkbox"/> Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.</p><p><input checked="" type="checkbox"/> PTO suggested wording for terminal disclaimer was unchanged.</p><p><input type="checkbox"/> Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.</p></div>			

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b>			Docket No. <b>ISPH-0625</b>
Applicant(s): <b>Brett P. Monia</b>			
Serial No. <b>10/057,550</b>	Filing Date <b>January 25, 2002</b>	Examiner <b>James Schultz</b>	Group Art Unit <b>1635</b>
Invention: <b>ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION</b>			
<p>I hereby certify that this _____ <b>Terminal Disclaimer</b> _____  <i>(Identify type of correspondence)</i></p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <b>703-872-9306</b> )</p> <p>on <u>February 27, 2004</u>  <i>(Date)</i></p> <div style="text-align: right; margin-top: 100px;"> <u>Jane Massey Licata</u>  <i>(Typed or Printed Name of Person Signing Certificate)</i>    <u></u>  <i>(Signature)</i> </div>			
<b>Note: Each paper must have its own certificate of mailing.</b>			

**Terminal Disclaimer To Obviate A Double  
Patenting Rejection Over A Prior Patent**Docket No.  
**ISPH-0625**In Re Application Of: **Brett P. Monia**Serial No.  
**10/057,550**Filing Date  
**January 25, 2002**Examiner  
**James Schultz**Group Art Unit  
**1635**Invention: **ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION**Owner of Record: **Isis Pharmaceuticals, Inc.****TO THE COMMISSIONER FOR PATENTS:**

The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,358,932. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.


  
\_\_\_\_\_  
Signature

Dated: **February 27, 2004**

**Jane Massey Licata**  
\_\_\_\_\_  
Typed or Printed Name

- ☒ Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  
☒ PTO suggested wording for terminal disclaimer was unchanged.  
☐ Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.



<b>Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent</b>			Docket No. <b>ISPH-0625</b>
In Re Application Of: <b>Brett P. Monia</b>			
Serial No. <b>10/057,550</b>	Filing Date <b>January 25, 2002</b>	Examiner <b>James Schultz</b>	Group Art Unit <b>1635</b>
Invention: <b>ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION</b>			
Owner of Record: <b>Isis Pharmaceuticals, Inc.</b>			
<u><b>TO THE COMMISSIONER FOR PATENTS:</b></u>			
<p>The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,919,773. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.</p> <p>In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.</p> <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney of record.</p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"><div style="text-align: center;"> _____ <i>Signature</i> <b>Jane Massey Licata</b> <i>Typed or Printed Name</i></div><div style="text-align: right;">Dated: February 27, 2004</div></div> <div style="margin-top: 10px;"><input checked="" type="checkbox"/> Terminal disclaimer fee under 37 C.F.R. 1.20(d) included. <input type="checkbox"/> PTO suggested wording for terminal disclaimer was unchanged. <input type="checkbox"/> Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.</div>			

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)		
Applicant(s): Brett P. Monia		
Docket No.	ISPH-0625	
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz
		Group Art Unit 1635
Invention: ANTISENSE OLIGONUCLEOTIDE MODULATION BY RAF GENE EXPRESSION		
I hereby certify that this _____ <div>(Identify type of correspondence)</div>	Terminal Disclaimer <div>(Identify type of correspondence)</div>	
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306 )		
on February 27, 2004 <div>(Date)</div>	Jane Massey Licata <div>(Typed or Printed Name of Person Signing Certificate)</div>	
<div>J.M.Licata</div> <div>(Signature)</div>		
Note: Each paper must have its own certificate of mailing.		

**Terminal Disclaimer To Obviate A Double  
Patenting Rejection Over A Prior Patent**Docket No.  
ISPH-0625In Re Application Of: **Brett P. Monia**Serial No.  
10/057,550Filing Date  
January 25, 2002Examiner  
James SchultzGroup Art Unit  
1635Invention: **ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION**Owner of Record: **Isis Pharmaceuticals, Inc.****TO THE COMMISSIONER FOR PATENTS:**

The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,744,362. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.



Signature

Dated: February 27, 2004

Jane Massey Licata

Typed or Printed Name

- ☒ Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  
☐ PTO suggested wording for terminal disclaimer was unchanged.  
☐ Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.